system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Adiponectin, Adult, Anti-Inflammatory Agents, Blood Glucose, Body Mass Index, C-Reactive Protein, Cholesterol, HDL, Cytokines, Dehydroepiandrosterone, Double-Blind Method, Female, Glucose Intolerance, Humans, Hypoglycemic Agents, Inflammation, Insulin, Insulin Resistance, Leukocytes, Mononuclear, Lipopolysaccharides, Male, Obesity.
user
Does a synthetic anti-inflammatory sterol improve insulin sensitivity in insulin-resistant obese impaired glucose tolerance subjects? Context: To study the activity of HE3286 (17α-ethynylandrost-5-ene-3β,7β,17β-triol), an anti-inflammatory sterol that is active in models of obesity-induced inflammation and insulin resistance in high body mass index (BMI) subjects with impaired glucose tolerance (IGT). HE3286 was explored in high BMI IGT subjects using hyperinsulinemic, euglycemic clamp studies. In insulin-resistant subjects, HE3286 significantly increased day 29 insulin-stimulated glucose disposal and HDL cholesterol, and decreased C-reactive protein (CRP) compared to placebo. For HE3286, change in M value showed a significant negative correlation with baseline M value. Subjects with baseline M value below the median (4.2 mg/kg/min) had significantly lower adiponectin and higher lipopolysaccharide-stimulated peripheral blood mononuclear cell cytokine secretion. After 28 days of HE3286 treatment, adiponectin levels were significantly increased in insulin-resistant (baseline M < 4.2), but not insulin-sensitive (baseline M > 4.2) subjects, compared to placebo.
assistant
HE3286 significantly increased the frequency of subjects with increased insulin-stimulated glucose disposal and HDL, and decreased CRP compared to placebo, in insulin-resistant, but not insulin-sensitive subjects. Thus, HE3286 may preferentially benefit insulin-resistant, inflamed, high BMI IGT subjects. Final Decision: yes